BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ATP2B3, PMCA3, 492, ENSG00000067842 AND Treatment
16 results:

  • 1. Spatial-Temporal Trends in ovarian cancer Outcomes in California.
    Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
    JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36238987
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
    Manganaro L; Celli V; Viggiani V; Berardelli E; Granato T; Tartaglione S; Farina A; Catalano C; Angeloni A; Anastasi E
    Tumour Biol; 2022; 44(1):171-185. PubMed ID: 36093649
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Embryonal Rhabdomyosarcoma of the Uterine Cervix: A Clinicopathologic Study of 94 Cases Emphasizing Issues in Differential Diagnosis Staging, and Prognostic Factors.
    Devins KM; Young RH; Ghioni M; Burandt E; Bennett JA; Oliva E
    Am J Surg Pathol; 2022 Nov; 46(11):1477-1489. PubMed ID: 35941719
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
    Perri T; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Fertil Steril; 2021 Aug; 116(2):538-545. PubMed ID: 33823990
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
    Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical characteristics and survival outcomes of patients with both primary breast cancer and primary ovarian cancer.
    Chen C; Xu Y; Huang X; Mao F; Shen S; Xu Y; Sun Q
    Medicine (Baltimore); 2020 Aug; 99(32):e21560. PubMed ID: 32769897
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7.
    Wang Z; Liu Y; Wang M; Zhao J
    J BUON; 2020; 25(2):797-804. PubMed ID: 32521870
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.
    Wu J; Blair J; Izevbigie OC; Wright NC; Arend RC
    Gynecol Oncol; 2018 Sep; 150(3):494-500. PubMed ID: 29970241
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [A retrospective study of tumor and fertility outcomes after fertility-sparing surgical treatment of patients with borderline ovarian tumors].
    Liu F; Hu DH; Zhang YF; Wang B; Huang K; Wang CY; Xia XY
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3699-3703. PubMed ID: 29325322
    [No Abstract]    [Full Text] [Related]  

  • 10. Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.
    Terenziani M; Bisogno G; Boldrini R; Cecchetto G; Conte M; Boschetti L; De Pasquale MD; Biasoni D; Inserra A; Siracusa F; Basso ME; De Leonardis F; Di Pinto D; Barretta F; Spreafico F; D'Angelo P
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449306
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
    Lambertini M; Ceppi M; Poggio F; Peccatori FA; Azim HA; Ugolini D; Pronzato P; Loibl S; Moore HC; Partridge AH; Bruzzi P; Del Mastro L
    Ann Oncol; 2015 Dec; 26(12):2408-19. PubMed ID: 26347105
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.
    Peng L; Zhu H; Wang J; Sui H; Zhang H; Jin C; Li L; Xu T; Miao R
    Mol Cell Biochem; 2015 Jul; 405(1-2):73-9. PubMed ID: 25862460
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
    Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
    Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
    Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
    Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
    von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J
    Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.